GlassScriptPhysician profile
Tai Nguyen
NPI 1275823916
$9,861.62
in general payments reported to CMS, 2019-2025
39 companies · $1,442 in 2025
The $1,442 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $935 · 2020: $1,408 · 2021: $1,948 · 2022: $1,344 · 2023: $1,477 · 2024: $1,308 · 2025: $1,442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,227.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,138.82 | 2021-2025 | |
| Glaxosmithkline, LLC. | $1,234.76 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $800.39 | 2019-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $592.64 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $586.45 | 2019-2024 | Jardiance |
| Pfizer INC. | $562.43 | 2020-2025 | |
| Novo Nordisk INC | $478.11 | 2020-2025 | |
| Horizon Therapeutics Plc | $478.11 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $364.70 | 2019-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $314.45 | 2022-2024 | |
| Amgen INC. | $259.34 | 2020-2025 | Repatha, Otezla, Repatha |
| Biohaven Pharmaceuticals, INC. | $203.48 | 2020-2021 | |
| Orexo US, INC. | $193.54 | 2019 | |
| Astellas Pharma US INC | $171.37 | 2023-2025 | Veozah |
| Merck Sharp & Dohme LLC | $166.86 | 2019-2024 | Gardasil 9, Belsomra, Capvaxive |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tai Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.